-- Date: Monday, October 13, 2008 -- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT) -- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942 International Telephonic Replay: A playback of the conference call will be available from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20, 2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 9164451
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.
SOURCE Neurobiological Technologies, Inc.